Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Medicine, Internal medicine, Capecitabine, Lapatinib, Neutropenia, and Triple-negative breast cancer.
ACE-Breast-02: a randomized phase III trial of ARX788 versus lapatinib plus capecitabine for HER2-positive advanced breast cancer
ACE-Breast-02: A pivotal phase II/III trial of ARX788, a novel anti-HER2 antibody-drug conjugate (ADC), versus lapatinib plus capecitabine for HER2+ advanced breast cancer (ABC).
ARX788 Versus Lapatinib Plus Capecitabine in the Second-Line Treatment of HER2-Positive Advanced Breast Cancer (ACE-Breast-02): A Multicentre, Open-Label, Phase III, Randomised Controlled Trial
PLEASURABLE: Results and biomarkers analysis from the phase II study of dalpiciclib combined with pyrotinib and endocrine therapy (ET) in women with dual-receptor positive (ER+/HER2+) metastatic breast cancer (MBC).
Exosomal annexin A6 induces gemcitabine resistance by inhibiting ubiquitination and degradation of EGFR in triple-negative breast cancer
Advantages with prophylactic PEG-rhG-CSF versus rhG-CSF in breast cancer patients receiving multiple cycles of myelosuppressive chemotherapy: an open-label, randomized, multicenter phase III study
Cisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer